The Discounted Cash Flow (DCF) valuation of Hansa Biopharma AB (HNSA.ST) is (1,440.11) SEK. With the latest stock price at 30.52 SEK, the upside of Hansa Biopharma AB based on DCF is -4818.6%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.0% - 8.8% | 6.9% |
| Long-term Growth Rate | 3.0% - 4.7% | 3.9% |
| Fair Price | (17,113.24) - (765.84) | (1,440.11) |
| Upside | -56172.2% - -2609.3% | -4818.6% |